Skip to content

VR and Scrip Training of PWA, Randomized Controlled Trial

Can Immersive Virtual Reality Magnify Treatment Outcomes of Script Training on Cantonese Speakers with Chronic Aphasia: a Randomized Controlled Trial

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06722092
Acronym
VRSTPWA
Enrollment
105
Registered
2024-12-09
Start date
2025-06-30
Completion date
2028-06-30
Last updated
2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aphasia, Acquired, Chronic Stroke

Keywords

functional communication, randomized controlled trial, script training, immersive reality, aphasia intervention

Brief summary

The goal of this RCT is to investigate if computerized script training may promote functional communication and nonverbal cognitive functions of Cantonese-speaking PWA, and whether VR may further magnify the treatment outcomes. The main research questions are: 1. Can script training promote verbal functional communication of Cantonese-speaking PWA? 2. Can script training enhance nonverbal cognitive functions of Cantonese-speaking PWA? 3. Can VR magnify verbal and nonverbal treatment outcomes of script training of PWA?

Interventions

The PWA will wear a head-mounted VR device (e.g., Metaverse Oculus Quest 2 or other commercially available devices) for 30 minutes, which intends to create an immersive environment for training. Scripts trained in the computerized script training program in a particular session will be practiced. Cinematic 360˚ photo-real scenarios of daily contexts such as a restaurant or a grocery store will be displayed in the device while a communication partner, e.g., a waiter in the restaurant or a shopkeeper of a grocery store will initiate the conversation by producing the corresponding part of the script. The PWA will be given time to respond. Upon the completion of PWA's respond, the next conversational turn will be initiated. The clinical assistant, who accompanies the PWA in the entire training session, will control the flow of the 360 ˚ videos.

The flow of training is identical to the VR condition, except that photos depicting the scenarios and prerecorded conversational turns will be presented to the PWA on a computer screen with the same procedures mentioned in the VR condition.

Sponsors

Prof FONG NAI KUEN KENNETH
CollaboratorUNKNOWN
Dr LI SHI PUI
CollaboratorUNKNOWN
Dr NG HIU FUNG PETER
CollaboratorUNKNOWN
Johns Hopkins University
CollaboratorOTHER
The Hong Kong Polytechnic University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. a stroke onset more than six months, with an Aphasia Quotient (AQ) below 96.4, as evaluated by the Cantonese version of Western Aphasia Battery (CAB; Yiu, 1992), 2. premorbid fluent Cantonese speakers, 3. aged between 30 and 80 years, 4. no reported progressive neurogenic disorders such as dementia or Parkinson's disease, 5. no motor speech disorders of moderate to severe level, and 6. normal or corrected-to-normal vision and hearing functions

Exclusion criteria

1. concurrent participation in other aphasia treatment trials, and 2. incompatibility with immersive VR exposure such as complains of nausea, headache, or other severe discomforts during trial use of a head-mounted device during screening.

Design outcomes

Primary

MeasureTime frameDescription
Percentage accuracy of treatment probe correctly producedFrom baseline up to 8-week post trainingParticipant's production accuracy of the trained scripts in read-aloud and no-cue conditions.
Time to produce each of the scripts in the treatment probeFrom baseline up to 8-week post trainingParticipant's production time of the trained scripts in read-aloud and no-cue conditions.
Number of sessions to reach performance criteria in session probeFrom baseline up to 8-week post training

Secondary

MeasureTime frameDescription
Subtest 1 (map search) and 3 (elevator counting) of Test of Everyday Attention to assess attentionFrom baseline up to 8-week post trainingThe sub-test 1 aims to tap sustained and selective visual attention via identifying the target symbol in a map while the sub-test 3 assesses auditory selective attention via counting the number of target tones in the presence of distractors with different tones.
Digit span forward and backward task to assess verbal short-term and working memoryFrom baseline up to 8-week post trainingThe longest span of participant correctly recalled in the digit span forward and backward task.
Cantonese version of the Western Aphasia Battery (CAB) to measure aphasia severityFrom baseline up to 8-week post training
Wisconsin Card Sort Test (WCST) to assess executive functionFrom baseline up to 8-week post trainingWCST assesses cognitive flexibility and reasoning via matching cards with respect to color, quantity, and shape upon different rules and feedback given.
Test of Nonverbal Intelligence-third edition (TONI-3) to assess executive functionFrom baseline up to 8-week post trainingA norm-referenced test that uses abstract figures to evaluate abstract reasoning and problem-solving.
Cantonese version of the Amsterdam-Nijmegen Everyday Language Test to measure verbal communication effectiveness in conversation via 20 culturally appropriate scenariosFrom baseline up to 8-week post training
Cantonese version of the 20-item Communication Outcome after Stroke (Can-COAST) as a self-reported outcome on communication and quality of lifeFrom baseline up to 8-week post trainingThe questionnaire consists of 20 questions, and participants will be asked to evaluate their functional communication and quality of life based on a 5-point Likert scale. Higher scores reflect better functional communication performance and quality of life.

Contacts

Primary ContactWinsy WS Wong, PhD
wszewong@polyu.edu.hk852-34003117

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 4, 2026